ReviewPaediatric respiratory reviews2015
Biomarkers of respiratory syncytial virus (RSV) infection: specific neutrophil and cytokine levels provide increased accuracy in predicting disease severity.
Review in Paediatric respiratory reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Burden of respiratory syncytial virus (RSV) infection in Germany: a systematic review.BMC infectious diseases · 2024Pooled it
- A Meta-Analysis of Multiple Whole Blood Gene Expression Data Unveils a Diagnostic Host-Response Transcript Signature for Respiratory Syncytial Virus.International journal of molecular sciences · 2020Pooled it
- Nasal-spraying Bacillus spores as an effective symptomatic treatment for children with acute respiratory syncytial virus infection.Scientific reports · 2022Trial
- A Retrospective Unicenter Study of Clinical and Inflammatory Features in Hospitalized Adults with Respiratory Syncytial Virus Infection Across Two Epidemic Waves in Catalonia, Spain.Journal of clinical medicine · 2026Article
- Aging and vaccines: impact of immunosenescence and inflammaging in vaccine response.Frontiers in aging · 2026Review
- Review
- Serum immunoglobulin A as a biomarker for respiratory syncytial virus infection in children aged <2 years.ERJ open research · 2025Article
- Predictive Factors and Clinical Markers of Recurrent Wheezing and Asthma After RSV Infection.Viruses · 2025Review
- Innovative biomarkers TCN2 and LY6E can significantly inhibit respiratory syncytial virus infection.Journal of translational medicine · 2024Article
- Reduced Serum Brain-Derived Neurotrophic Factor in Infants Affected by Severe Bronchiolitis.Current neuropharmacology · 2024Article
- Article
- ON-1 and BA-IX Are the Dominant Sub-Genotypes of Human Orthopneumovirus A&B in Riyadh, Saudi Arabia.Genes · 2022Article
- Impact of genetic polymorphisms related to innate immune response on respiratory syncytial virus infection in children.Virus genes · 2022Review
- Identification of biomarkers for disease severity in nasopharyngeal secretions of infants with upper or lower respiratory tract viral infections.Clinical and experimental immunology · 2022Observational
- Interleukin-6 and granulocyte colony-stimulating factor as predictors of the prognosis of influenza-associated pneumonia.BMC infectious diseases · 2022Article
- Balancing precision versus cohort transcriptomic analysis of acute and recovery phase of viral bronchiolitis.American journal of physiology. Lung cellular and molecular physiology · 2021Article
- Electrochemical sensing: A prognostic tool in the fight against COVID-19.Trends in analytical chemistry : TRAC · 2021Review
- Airway gene-expression classifiers for respiratory syncytial virus (RSV) disease severity in infants.BMC medical genomics · 2021Article
- Urinary club cell protein 16 (CC16): Utility of its assay during acute bronchiolitis.Pediatric pulmonology · 2020Article
- Left Ventricular Dysfunction and Plasmatic NT-proBNP Are Associated with Adverse Evolution in Respiratory Syncytial Virus Bronchiolitis.Diagnostics (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Despite fundamental advances in the research on respiratory syncytial virus (RSV) since its initial identification almost 60 years ago, recurring failures in developing vaccines and pharmacologic strategies effective in controlling the infection have allowed RSV to become a leading cause of global infant morbidity and mortality. Indeed, the burden of this infection on families and health care organizations worldwide continues to escalate and its financial costs are growing. Furthermore, strong epidemiologic evidence indicates that early-life lower respiratory tract infections caused by RSV lead to the development of recurrent wheezing and childhood asthma. While some progress has been made in the identification of reliable biomarkers for RSV bronchiolitis, a "one size fits all" biomarker capable of accurately and consistently predicting disease severity and post-acute outcomes has yet to be discovered. Therefore, it is of great importance on a global scale to identify useful biomarkers for this infection that will allow pediatricians to cost-effectively predict the clinical course of the disease, as well as monitor the efficacy of new therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.